Ethical Questions Linked to Rare Diseases and Orphan Drugs – A Systematic Review

References

• European Commision. Rare diseases | health - research and innovation - European commission. Published 2016 Available from: http://ec.europa.eu/research/health/index.cfm?pg=area&areaname=rare. Accessed 825, 2018.
   Google Scholar
• European Union of Private Hospitals. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. Published 2016 Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140002. Accessed 825, 2018.
   Google Scholar
• RARE Facts. Global genes. Available from: https://globalgenes.org/rare-facts/. Accessed 720, 2020.
   Google Scholar
• Pinxten W, Denier Y, Dooms M, Cassiman -J-J, Dierickx K. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation. J Med Ethics. 2012;38(3):148–153. doi:10.1136/medethics-2011-10009421947805
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Orphanet J Rare Dis. 2017;12(1):1–8. doi:10.1186/s13023-016-0551-728057032
   PubMed Web of Science ®Google Scholar
• WMA - The World Medical Association. WMA declaration of Helsinki – ethical principles for medical research involving human subjects. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 429, 2020.
   Google Scholar
• Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics. 2005;31(3):164–168. doi:10.1136/jme.2003.00713815738438
   PubMed Web of Science ®Google Scholar
• Europeen Comission. EU charter of fundamental rights. European Commission - European Commission. Published 2018 Available from: https://ec.europa.eu/info/aid-development-cooperation-fundamental-rights/your-rights-eu/eu-charter-fundamental-rights_en. Accessed 825, 2018.
   Google Scholar
• Picavet E, Cassiman D, Pinxten W, Simoens S. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium. Expert Rev Pharmacoecon Outcomes Res. 2013;13(5):571–573. doi:10.1586/14737167.2013.83262624138643
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005;331(7523):1016–1019. doi:10.1136/bmj.331.7523.101616254305
   PubMed Web of Science ®Google Scholar
• van der Burg S, Oerlemans A. Fostering caring relationships: suggestions to rethink liberal perspectives on the ethics of newborn screening. Bioethics. 2018;32(3):171–183. doi:10.1111/bioe.1242529442381
   PubMed Web of Science ®Google Scholar
• Kinney J. Health disparities: exploring the ethics of orphan drugs. Am J Health Syst Pharm. 2014;71(9):692–693. doi:10.2146/ajhp13034824733129
   PubMed Web of Science ®Google Scholar
• Farberov L, Gilam A, Isakov O, Shomron N. Meeting summary: ethical aspects of whole exome and whole genome sequencing studies (WES/WGS) in rare diseases, Tel Aviv, Israel, January 2013. Genet Res. 2013;95(2–3):53–56. doi:10.1017/S0016672313000104
   Web of Science ®Google Scholar
• Gliklich RE, Dreyer NA, Leavy MB. Principles of Registry Ethics, Data Ownership, and Privacy. Agency for Healthcare Research and Quality (US); 2014 Available from: https://www.ncbi.nlm.nih.gov/books/NBK208620/. Accessed 722, 2020.
   Google Scholar
• Ludvigsson JF, Håberg SE, Knudsen GP, et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol. 2015;7:491. doi:10.2147/CLEP.S9058926648756
   PubMed Web of Science ®Google Scholar
• McCormack P, Woods S, Aartsma-Rus A, et al. Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: “translating” the translational. PLoS Curr. 2013;5. doi:10.1371/currents.md.f90b49429fa814bd26c5b22b13d773ec
   Google Scholar
• Nguyen MT, Goldblatt J, Isasi R, et al. Model consent clauses for rare disease research. BMC Med Ethics. 2019;20(1):55. doi:10.1186/s12910-019-0390-x31370847
   PubMed Web of Science ®Google Scholar
• Duchange N, Darquy S, d’Audiffret D, et al. Ethical management in the constitution of a European database for leukodystrophies rare diseases. Eur J Paediatr Neurol. 2014;18(5):597–603. doi:10.1016/j.ejpn.2014.04.00224786336
   PubMed Web of Science ®Google Scholar
• Leung XY, Sun J, Bai B. Bibliometrics of social media research: a co-citation and co-word analysis. Int J Hosp Manag. 2017;66:35–45. doi:10.1016/j.ijhm.2017.06.012
   Web of Science ®Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. doi:10.1080/1364557032000119616
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.100009719621072
   PubMed Web of Science ®Google Scholar
• Juth N. For the sake of justice: should we prioritize rare diseases? Health Care Anal. 2017;25(1):1–20. doi:10.1007/s10728-014-0284-525145639
   PubMed Web of Science ®Google Scholar
• Taylor C, Jan S, Thompson K. Funding therapies for rare diseases: an ethical dilemma with a potential solution. Aust Health Rev. 2018;42(1):117–119. doi:10.1071/AH1619428202130
   PubMed Web of Science ®Google Scholar
• Boy R, Schwartz IVD, Krug BC, et al. Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I. J Med Ethics. 2011;37(4):233–239. doi:10.1136/jme.2010.03715021266385
   PubMed Web of Science ®Google Scholar
• Hews‐Girard J, Obilar HN, Plazas PC. Objectivity in rare disease research: a philosophical approach. Nurs Inq. 2020;27(1):e12323. doi:10.1111/nin.1232331863629
   PubMed Web of Science ®Google Scholar
• Jarosławski S, Toumi M. Non-profit drug research and development: the case study of Genethon. J Mark Access Health Policy. 2018;7(1). doi:10.1080/20016689.2018.1545514
   Google Scholar
• Wellman-Labadie O, Zhou Y. The US orphan drug act: rare disease research stimulator or commercial opportunity? Health Policy Amst Neth. 2010;95(2–3):216–228. doi:10.1016/j.healthpol.2009.12.001
   PubMed Web of Science ®Google Scholar
• Hyry HI, Manuel J, Cox TM, Roos JCP. Compassionate use of orphan drugs. Orphanet J Rare Dis. 2015;10. doi:10.1186/s13023-015-0306-x
   Web of Science ®Google Scholar
• Kesselheim AS. Ethical considerations in orphan drug approval and use. Clin Pharmacol Ther. 2012;92(2):153–155. doi:10.1038/clpt.2012.9222814660
   PubMed Web of Science ®Google Scholar
• Rosselli D, Rueda J-D, Solano M. Ethical and economic considerations of rare diseases in ethnic minorities: the case of mucopolysaccharidosis VI in Colombia. J Med Ethics. 2012;38(11):699–700. doi:10.1136/medethics-2011-10020422550061
   PubMed Web of Science ®Google Scholar
• Gelinas L, Crawford B, Kelman A, Bierer BE. Relocation of study participants for rare and ultra-rare disease trials: ethics and operations. Contemp Clin Trials. 2019;84:105812. doi:10.1016/j.cct.2019.10581231330189
   PubMed Web of Science ®Google Scholar
• Afroze B, Brown N. Ethical issues in managing Lysosomal storage disorders in children in low and middle income countries. Pak J Med Sci. 2017;33(4):1036–1041. doi:10.12669/pjms.334.1297529067088
   PubMed Web of Science ®Google Scholar
• Schmiedeke E, Schaefer S, Aminoff D, Schwarzer N, Jenetzky E. Non-financial conflicts of interest: contribution to a surgical dilemma by the European reference networks for rare diseases. Pediatr Surg Int. 2019;35(9):999–1004. doi:10.1007/s00383-019-04516-y31278479
   PubMed Web of Science ®Google Scholar
• Encina G, Castillo-Laborde C, Lecaros JA, et al. Rare diseases in Chile: challenges and recommendations in universal health coverage context. Orphanet J Rare Dis. 2019;14(1):289. doi:10.1186/s13023-019-1261-831931841
   PubMed Web of Science ®Google Scholar
• Barrera LA, Galindo GC. Ethical aspects on rare diseases. Adv Exp Med Biol. 2010;686:493–511. doi:10.1007/978-90-481-9485-8_2720824462
   PubMed Web of Science ®Google Scholar
• Hansson MG, Gattorno M, Forsberg JS, Feltelius N, Martini A, Ruperto N. Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases. Arch Dis Child. 2012;97(6):561–563. doi:10.1136/archdischild-2011-30117522362719
   PubMed Web of Science ®Google Scholar
• Gershon ES, Alliey-Rodriguez N. New ethical issues for genetic counseling in common mental disorders. Am J Psychiatry. 2013;170(9):968–976. doi:10.1176/appi.ajp.2013.1212155823897273
   PubMed Web of Science ®Google Scholar
• European Comission. The charter of fundamental rights of the European Union. Published online 2008.
   Google Scholar
• Hollak CE, Aerts JM, Aymé S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis. 2011;6:16. doi:10.1186/1750-1172-6-1621496291
   PubMed Web of Science ®Google Scholar
• Wolf U. Com l’ètica de la compassió de Schopenhauer pot contribuir al debat ètic d’avui. Enrahonar Int J Theor Pract Reason. 2015;55:41–49. doi:10.5565/rev/enrahonar.207
   Google Scholar